German-based BiomedX Innovation Center and Velabs Therapeutics announced an exciting collaboration to capitalize on Velab’s microfluidics-based technology in the field of T-cell screening.
Biomed X Innovation Center, based in Heidelberg, Germany, says it is a creator of “biomedical innovation outside of the pharma box.” It represents an interface between academia and industry to produce new breakthroughs. Employing approximately 50 to 75 people, it includes distinguished early-career scientists recruited from all over the world who work on novel pre-clinical research projects in the fields of biomedicine, molecular biology, cell biology, diagnostics and consumer care. These interdisciplinary project teams conduct groundbreaking biomedical research in an open innovation lab facility on the campus of the University of Heidelberg, Germany. Each team is typically sponsored by a corporate pharma or biotech partner of BioMed X. After a fully funded project term, successful projects are either internalized into the development pipeline of the respective pharma or biotech partner, or transformed into an independent start-up company. BioMed X collaborates with pharma companies such as AbbVie, Boehringer Ingelheim, Johnson & Johnson, Merck and Roche.
Velabs Therapeutics is a spin-out from Europe’s most prestigious life-science research and instrumentation institute, the European Molecular Biology Laboratory (EMBL), which stands at the forefront of microfluidics-based screening technology and applications world-wide.
The company’s droplet-based microfluidic screening technology aims at the fast generation of antibodies against target molecules presented on cellular membrane surfaces or as soluble protein. VELABS has pioneered the use of droplet microfluidics for the fast screening of correctly paired human antibodies that do not just bind to a drug target, but rather modulate its function.